Lyme Disease Vaccine Candidate Proven Safe in Children
A 4-dose clinical trial involving children aged 5 to 17 showed the LB6V vaccine had a safety profile comparable to a placebo.
Updated on Oct. 6, 2026 in Children’s Health
Live Poll
Would you trust the safety results of a new vaccine study for your children?
An investigational Lyme disease vaccine, LB6V, demonstrated safety and tolerability in children and adolescents aged 5 to 17 during a large-scale clinical trial. Results presented at the 2026 American Academy of Pediatrics Annual Meeting on October 6, 2026, indicate that serious adverse event rates were consistent between the vaccine and placebo groups.
Why it matters
These findings are a significant step in the development of a pediatric-specific preventive measure for Lyme disease. Establishing a safe vaccine profile is essential for future efforts to reduce the burden of tick-borne illness in the U.S. pediatric population.
In a randomized trial of 3,547 participants aged 5 to 17, the LB6V vaccine was compared against a saline placebo across 57 U.S. sites. The study found serious adverse events occurred in 1.6% of both groups, though local reactions were reported in 89.1% of vaccine recipients versus 44.5% of the placebo group.
The players
American Academy of Pediatrics
A professional organization dedicated to the health and well-being of infants, children, and adolescents.
The details
The LB6V trial utilized a 4-dose series administered at months 0, 2, 6, and 18 to trigger an immune response. While local reactions were more common in the vaccine group, systemic events were reported in 79.8% of vaccine recipients compared to 61.5% in the placebo group. The trial maintained high safety standards, with less than 1% of participants in either group withdrawing due to adverse events.
Timeline
December 12, 2022: Trial enrollment and data collection began.
July 21, 2025: Trial data collection concluded.
October 6, 2026: Study results were presented at the AAP Annual Meeting.
Health Landscape
The study of LB6V represents a critical expansion of the research pipeline targeting pediatric Lyme disease prevention. It builds upon existing efforts to address tick-borne illness by providing necessary safety data to support the potential inclusion of Lyme vaccines in future childhood immunization schedules.
These results indicate that the LB6V vaccine was well-tolerated in clinical testing, but parents should recognize that this is a research finding rather than an available treatment. Discussing tick-bite prevention strategies with your pediatrician remains the primary way to manage Lyme risk for children.
The takeaway
This trial shows that the LB6V Lyme disease vaccine candidate had a safety profile comparable to a placebo in children and adolescents. Families should continue to prioritize physical tick-bite prevention measures, such as performing thorough skin checks after being outdoors in wooded or grassy areas.
Further reading
For more on evolving standards in pediatric immunization, visit Children’s Health.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Would you trust the safety results of a new vaccine study for your children?
